Thursday, April 30, 2020 10:18:51 AM
I tuned into the webcast. Obviously, no mention of Lexaria, however there were a few comments made about the product on! and something about adjusting it for the FDA (don't quote me on this...I need to go back and listen a second time). A ton of the questions after the presentation were about decreasing costs and keeping future product costs down. Obvious I could speculate that there is still something going on between the two companies...but there is just no proof. I email Altria Investor Relations a while ago and they told me to talk to Chris. I keep checking the SEDAR and EDGAR pages for announcements...no dice. With it being the last day in April it would be nice for Chris to follow up on his comments regarding 'Altria decision by the end of April'...even if it just to announce that the decision date defined in the agreement has been extended due to new executive management at Altria and/or the COVID19 situation.
Recent LEXX News
- Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property • ACCESS Newswire • 04/15/2026 01:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/13/2026 05:07:36 PM
- Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval • ACCESS Newswire • 04/07/2026 01:10:00 PM
- Lexaria to Begin New Human Clinical Study in GLP-1 • ACCESS Newswire • 04/01/2026 01:20:00 PM
- Lexaria's Robust Patent Portfolio Continues to Grow • ACCESS Newswire • 03/26/2026 01:20:00 PM
- Lexaria's Oral GLP-1 Drug Strategy Validated by Industry • ACCESS Newswire • 03/24/2026 01:15:00 PM
- Lexaria Announces New R&D Plans for 2026 • ACCESS Newswire • 03/04/2026 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 09:30:40 PM
- Lexaria Announces Positive Final Results From Human Pilot Study #5 • ACCESS Newswire • 02/05/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 06:51:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/28/2026 06:33:53 PM
- Lexaria Awarded Six Additional Patents • ACCESS Newswire • 01/22/2026 02:20:00 PM
- 5 Assets Securing the 2026 Biological Choke Point • GlobeNewswire Inc. • 01/21/2026 02:55:00 PM
- Lexaria Releases Annual Letter from the CEO • ACCESS Newswire • 01/12/2026 02:10:00 PM
- Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/30/2025 02:20:00 PM
- Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/23/2025 02:29:00 PM
- Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/16/2025 09:00:00 PM
- Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/15/2025 01:00:00 PM
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended • ACCESS Newswire • 11/12/2025 02:10:00 PM
- Lexaria Bioscience Corp. Provides Strategic Update • ACCESS Newswire • 10/09/2025 01:20:00 PM
- Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 09/29/2025 08:30:00 PM
- Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 09/26/2025 12:00:00 PM
- Lexaria Bioscience Shares Rise After Reaching GLP-1 Study Milestone • IH Market News • 08/14/2025 02:36:15 PM
